However, combined treatment with similar doses of γ-tocotrienol and rosiglitazone or troglitazone resulted in a significant increase in PPARγ and RXR expression in both MCF-7 and MDA-MB-231 breast cancer cell lines (Figures 5(a) and 5(b)). This evidence concerns the gene PPARG and breast cancer.